{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:13:45Z","timestamp":1767651225886},"reference-count":49,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,6,2]],"date-time":"2005-06-02T00:00:00Z","timestamp":1117670400000},"content-version":"vor","delay-in-days":4262,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Teratology"],"published-print":{"date-parts":[[1993,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Gemcitabine was given intravenously to female mice on gestation days (GD) 6\u201315 at doses of 0, 0.05, 0.25, or 1.5 mg\/kg\/day (0, 0.15, 0.75, or 4.5 mg\/m<jats:sup>2<\/jats:sup>\/day, respectively). Animals assigned to the teratology segment (25\/group) were killed on GD 18 for examination of maternal hematologic parameters and organ weights, as well as fetal viability, weights, and morphology. The postnatal segment females (20\/group) were allowed to deliver, and offspring physical, behavioral, and reproductive parameters were monitored. After offspring weaning, these dams were killed for hematologic and organ weight evaluations. At necropsy, 3 days after the final dose, the teratology segment dams showed dose\u2010related increases in spleen and thymus weights. These changes were accompanied by a dose\u2010related decrease in leukocytes and modest increases in mean corpuscular volume (MCV) and hemoglobin (MCH) at the two higher doses. On postpartum day (PPD) 21, the dams in the postnatal segment showed no treatment\u2010related effects on these organ weights or hematologic parameters, indicating recovery of these maternal parameters within 3.5 weeks following termination of treatment. The decreases in maternal body weight and food consumption observed during gestation, and in liver and uterine weights at term in the 1.5 mg\/kg\/day group, were considered to be secondary to a high rate of prenatal mortality, evidenced by increased resorptions in the teratology segment and decreased live litter size in both segments of the study. Additional indications of developmental toxicity in this dose group were an increased incidence of malformations, primarily cleft palate, decreased fetal weights in the teratology segment, and decreased neonatal survival in the postnatal segment. Other indications of offspring toxicity were decreased startle amplitude in the 0.05 and 1.5 mg\/kg\/day treatment\u2010derived males, and decreased ovarian weights in all F<jats:sub>1<\/jats:sub> females compared to controls. However, offspring growth, appearance of physical landmarks, F<jats:sub>1<\/jats:sub> activity levels, active and passive avoidance, and reproductive performance were not affected adversely in the surviving offspring of the 1.5 mg\/kg\/day treatment\u2010derived group or in mice from either of the two lower dose groups. These results indicate that maternal effects related to the antiproliferative actions of gemcitabine may be detected at doses below those which result in overt developmental toxicity, i.e., malformations, weight changes, and decreased prenatal and neonatal survival. \u00a9 1993 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/tera.1420480410","type":"journal-article","created":{"date-parts":[[2005,6,11]],"date-time":"2005-06-11T15:58:48Z","timestamp":1118505528000},"page":"365-381","source":"Crossref","is-referenced-by-count":10,"title":["Developmental toxicity of gemcitabine, an antimetabolite oncolytic, administered during gestation to CD\u20101 mice"],"prefix":"10.1002","volume":"48","author":[{"given":"J. A.","family":"Eudaly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P.","family":"Tizzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. L.","family":"Higdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. C.","family":"Todd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,6,2]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"669","article-title":"Collaborative behavioral teratology study: Protocol design and testing procedures","volume":"7","author":"Adams J.","year":"1985","journal-title":"Neurobehav. Toxicol. Teratol."},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmor.1051270303"},{"key":"e_1_2_1_4_1","first-page":"198","article-title":"Normal mouse erythropoiesis. I. The role of the spleen in mouse erythropoiesis","volume":"26","author":"Brodsky I.","year":"1966","journal-title":"Cancer Res."},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420260310"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420260309"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420270314"},{"key":"e_1_2_1_8_1","first-page":"591","article-title":"Collaborative behavioral teratology study: Results","volume":"7","author":"Buelke\u2010Sam J.","year":"1985","journal-title":"Neurobehav. Toxicol. Teratol."},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0892-0362(91)90074-7"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420070207"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(91)90225-4"},{"key":"e_1_2_1_12_1","first-page":"1202","volume-title":"The Pharmacological Basis of Therapeutics","author":"Calabresi P.","year":"1990"},{"key":"e_1_2_1_13_1","first-page":"181","article-title":"The teratogenic effects of the recent drugs active in cancer chemotherapy","volume":"3","author":"Chaube S.","year":"1968","journal-title":"Adv. Teratol."},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0273-2300(81)90082-9"},{"key":"e_1_2_1_15_1","volume-title":"Disposition of LY188011 in laboratory animals","author":"Culp H. W.","year":"1986"},{"key":"e_1_2_1_16_1","first-page":"307","volume-title":"Applied Statistics: Analysis of Variance and Regression","author":"Dunn O. J.","year":"1974"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.2307\/2528490"},{"key":"e_1_2_1_17_2","unstructured":"Food and Drug Administrationm(1978)Good laboratory practice for nonclinical laboratory studies. 21 CRF Part 58 good laboratory practice regulations; final rule."},{"key":"e_1_2_1_18_1","first-page":"429","volume-title":"Handbook of Teratology","author":"Gaylor D. W.","year":"1978"},{"key":"e_1_2_1_19_1","first-page":"6823","article-title":"Pharmacologically directed design of the dose rate and schedule of 2\u2032,2\u2032\u2010difluorodeoxycytidine (gemcitabine) administration in leukemia","volume":"50","author":"Grunewald R.","year":"1990","journal-title":"Cancer Res."},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420120209"},{"key":"e_1_2_1_21_1","first-page":"4024","article-title":"Comparison of the cellular pharmacokinetics and toxicity of 2\u2032,2\u2032\u2010difluorodeoxycytidine and 1\u2010\u03b2\u2010D\u2010arabinofuranosylcytosine","volume":"48","author":"Heinemann V.","year":"1988","journal-title":"Cancer Res."},{"key":"e_1_2_1_22_1","first-page":"4417","article-title":"Evaluation of the antitumor activity of gemcitabine (2\u2032,2\u2032\u2010difluoro\u20102\u2032\u2010deoxycytidine)","volume":"50","author":"Hertel L. W.","year":"1990","journal-title":"Cancer Res."},{"key":"e_1_2_1_23_1","first-page":"519","article-title":"Methylazoxymethanol as a developmental model of neurotoxicity","volume":"7","author":"Kabet K.","year":"1985","journal-title":"Neurobehav. Toxicol. Teratol."},{"key":"e_1_2_1_24_1","first-page":"13","article-title":"Common fetal aberrations and their teratologic significance: A review","volume":"1","author":"Khera K. S.","year":"1981","journal-title":"Fundam. Appl. Toxicol."},{"key":"e_1_2_1_25_1","first-page":"388","article-title":"Reversibilitat Pranataler Coffeinschaden bei Ratten [Reversibility of prenatal injuries induced by caffeine in rats]","volume":"5","author":"Leuschner F.","year":"1973","journal-title":"Colloq. Int. Chim. Cafes C. R."},{"key":"e_1_2_1_26_1","unstructured":"Madigan S.(1983) PC. ANOVA Version 1.0.Human Systems Dynamics Northridge CA."},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420440404"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-3219-0_5"},{"key":"e_1_2_1_28_1","first-page":"51","volume-title":"Methods in Prenatal Toxicology Evaluation of Embryotoxic Effects in Experimental Animals","author":"Palmer A. K.","year":"1977"},{"key":"e_1_2_1_29_1","first-page":"215","volume-title":"Handbook of Teratology","author":"Palmer A. K.","year":"1978"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/07328318908054215"},{"key":"e_1_2_1_31_1","first-page":"73","volume-title":"Developments in the Science and Practice of Toxicology","author":"Reiter L. W.","year":"1983"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-2189-7_9"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420190308"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420430308"},{"key":"e_1_2_1_34_2","volume-title":"SAS Users Guide: Statistics","author":"SAS Institute, Inc.","year":"1985"},{"key":"e_1_2_1_35_1","first-page":"432","volume-title":"SAS Users Guide: Statistics","author":"SAS Institute, Inc.","year":"1985"},{"key":"e_1_2_1_36_1","first-page":"403","volume-title":"SAS Users Guide: Statistics","author":"SAS Institute, Inc.","year":"1985"},{"key":"e_1_2_1_37_1","first-page":"579","volume-title":"SUGI Supplemental Library Users Guide","author":"SAS Institute, Inc.","year":"1986"},{"key":"e_1_2_1_38_1","first-page":"467","volume-title":"Chemically Induced Birth Defects","author":"Schardein J. L.","year":"1985"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0012-1606(71)90129-1"},{"key":"e_1_2_1_40_1","volume-title":"Plasma pharmacokinetics of gemcitabine in B6C3F1 mice, Fisher 344 rats, and beagle dogs","author":"Shipley L. A.","year":"1991"},{"key":"e_1_2_1_41_1","first-page":"104","volume-title":"Nonparametric Statistics for the Behavioral Sciences","author":"Siegel S.","year":"1956"},{"key":"e_1_2_1_42_1","first-page":"61","article-title":"Refinements in rapid clearing technique in the KOH\u2010Alizarin Red S method for fetal bone","volume":"39","author":"Staples R. E.","year":"1964","journal-title":"Stain Technol."},{"key":"e_1_2_1_43_1","first-page":"294","volume-title":"Congenital Malformations in Laboratory and Farm Animals. (Harcourt Brace Jovanovich)","author":"Szabo K. T.","year":"1989"},{"key":"e_1_2_1_44_1","first-page":"647","article-title":"Guidelines for developmental toxicity testing of chemicals in Japan","volume":"7","author":"Tanimura T.","year":"1985","journal-title":"Neurobehav. Toxicol. Teratol."},{"key":"e_1_2_1_45_1","volume-title":"A toxicological evaluation of LY188011 HCI given intraperitoneally to B6C3F1 mice for three months","author":"Todd G. C.","year":"1986"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-6264(70)80337-6"},{"key":"e_1_2_1_47_1","first-page":"262","volume-title":"Teratology: Principles and Techniques","author":"Wilson J. G.","year":"1965"}],"container-title":["Teratology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Ftera.1420480410","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/tera.1420480410","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:14:22Z","timestamp":1698192862000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/tera.1420480410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,10]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1993,10]]}},"alternative-id":["10.1002\/tera.1420480410"],"URL":"https:\/\/doi.org\/10.1002\/tera.1420480410","archive":["Portico"],"relation":{},"ISSN":["0040-3709","1096-9926"],"issn-type":[{"value":"0040-3709","type":"print"},{"value":"1096-9926","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,10]]}}}